Oxalate, inflammasome, and progression of kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 4, 2016, Pages 363-371

  Ermer, Theresa ^a   Eckardt, Kai Uwe ^a   Aronson, Peter S ^b   Knauf, Felix ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; inflammasome; innate immune system; oxalate

Indexed keywords

CRYOPYRIN; INFLAMMASOME; INTERLEUKIN 1BETA; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OXALIC ACID; OXALIC ACID DERIVATIVE;

BLOOD LEVEL; CELL INFILTRATION; CHRONIC KIDNEY DISEASE; CYTOKINE RELEASE; DISEASE COURSE; HOMEOSTASIS; HUMAN; HYPEROXALURIA; MACROPHAGE; NEPHRITIS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; ANIMAL; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; FIBROSIS; IMMUNOLOGY; INFLAMMATION; KIDNEY; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; FIBROSIS; HUMANS; INFLAMMASOMES; INFLAMMATION; INTERLEUKIN-1BETA; KIDNEY; MACROPHAGES; MICE; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OXALATES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84969228119     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000229     Document Type: Review

References (128)

1. Hagler L, Herman RH. Oxalate metabolism. I. Am J Clin Nutr 1973; 26:758-765.
2. Williams HE. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13:410-417.
3. Elder TD, Wyngaarden JB. The biosynthesis and turnover of oxalate in normal and hyperoxaluric subjects. J Clin Invest 1960; 39:1337-1344.
4. Schepers MSJ, van Ballegooijen ES, Bangma CH, Verkoelen CF. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int 2005; 68:1543-1553.
5. Glew RH, Sun Y, Horowitz BL, et al. Nephropathy in dietary hyperoxaluria: a potentially preventable acute or chronic kidney disease. World J Nephrol 2014; 3:122-142.
6. Brzica H, Breljak D, Burckhardt Birgitta C, et al. Oxalate: from the environment to kidney stones. Arch Ind Hyg Toxicol 2013; 64:609-630.
7. Asplin J. The management of patients with enteric hyperoxaluria. Urolithiasis 2015; 44:33-43.
8. Baker PRS, Cramer SD, Kennedy M, et al. Glycolate and glyoxylate metabolism in Hepg2 cells. Am J Physiol Cell Physiol 2004; 287:C1359-C1365.
9. Holmes RP, Assimos DG. Glyoxylate synthesis and its modulation and influence on oxalate synthesis. J Urol 1998; 160:1617-1624.
10. Poore RE, Hurst CH, Assimos DG, Holmes RP. Pathways of hepatic oxalate synthesis and their regulation. Am J Physiol Cell Physiol 1997; 272:C289-C294.
11. Farinelli MP, Richardson KE. Oxalate synthesis from [14c1]glycollate and [14c1]glyoxylate in the hepatectomized rat. Biochim Biophys Acta 1983; 757:8-14.
12. Knight J, Jiang J, Assimos DG, Holmes RP. Hydroxyproline ingestion and urinary oxalate and glycolate excretion. Kidney Int 2006; 70:1929-1934.
13. Takayama T, Fujita K, Suzuki K, et al. Control of oxalate formation from Lhydroxyproline in liver mitochondria. J Am Soc Nephrol 2003; 14:939-946.
14. Knight J, Assimos DG, Callahan MF, Holmes RP. Metabolism of primed, constant infusions of [1, 2-13c2] glycine and [1-13c1] phenylalanine to urinary oxalate. Metabolism 2011; 60:950-956.
15. Gambardella RL, Richardson KE. The pathways of oxalate formation from phenylalanine, tyrosine, tryptophan and ascorbic acid in the rat. Biochim Biophys Acta 1977; 499:156-168.
16. Beisswenger PJ, Howell SK, Russell GB, et al. Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products. Diabetes Care 2013; 36:3234-3239.
17. Rodrigues L, Matafome P, Crisostomo J, et al. Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation. J Physiol Biochem 2014; 70:173-184.
18. Zhu D, Wang L, Zhou Q, et al. (\+)-Catechin ameliorates diabetic nephropathy by trapping methylglyoxal in type 2 diabetic mice. Mol Nutr Food Res 2014; 58:2249-2260.
19. Waris S, Winklhofer-Roob BM, Roob JM, et al. Increased DNA dicarbonyl glycation and oxidation markers in patients with type 2 diabetes and link to diabetic nephropathy. J Diabetes Res 2015; 2015:915486.
20. Lapolla A, Flamini R, Vedova Antonio D, et al. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new Gc/Ms method. Clin Chem Lab Med 2003; 41:1166-1173.
21. Eisner BH, Porten SP, Bechis SK, Stoller ML. Diabetic kidney stone formers excrete more oxalate and have lower urine Ph than nondiabetic stone formers. J Urol 2010; 183:2244-2248.
22. Taylor EN, Curhan GC. Determinants of 24-hour urinary oxalate excretion. Clin J Am Soc Nephrol 2008; 3:1453-1460.
23. Knight J, Assimos DG, Easter L, Holmes RP. Metabolism of fructose to oxalate and glycolate. Horm Metab Res 2010; 42:868-873.
24. Knight J, Wood KD, Lange JN, et al. Oxalate formation from glyoxal in erythrocytes. Urology 2016; 88: 226. e11-226. e15.
25. Noonan SC, Savage GP. Oxalate content of foods and its effect on humans. Asia Pac J Clin Nutr 1999; 8:64-74.
26. Holmes RP, Kennedy M. Estimation of the oxalate content of foods and daily oxalate intake. Kidney Int 2000; 57:1662-1667.
27. Holmes RP, Ambrosius WT, Assimos DG. Dietary oxalate loads and renal oxalate handling. J Urol 2005; 174:943-947.
28. Chai W, Liebman M, Kynast-Gales S, Massey L. Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. Am J Kidney Dis 2004; 44:1060-1069.
29. Hatch M, Freel R. Intestinal transport of an obdurate anion: oxalate. Urol Res 2005; 33:1-16.
30. Chen Z, Ye Z, Zeng L, Yang W. Clinical investigation on gastric oxalate absorption. Chin Med J (Engl) 2003; 116:1749-1751.
31. Hautmann RE. The stomach: a new and powerful oxalate absorption site in man. J Urol 1993; 149:1401-1404.
32. Hatch M, Freel RW, Goldner AM, Earnest DL. Oxalate and chloride absorption by the rabbit colon: sensitivity to metabolic and anion transport inhibitors. Gut 1984; 25:232-237.
33. Voss S, Hesse A, Zimmermann DJ, et al. Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in healthy controls: measurements with the [13c2]oxalate absorption test. J Urol 2006; 175:1711-1715.
34. Sikora P, von Unruh GE, Beck B, et al. [Lsqb]13c2[Rsqb]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int 2008; 73:1181-1186.
35. von Unruh GE, Voss S, Sauerbruch T, Hesse A. Reference range for gastrointestinal oxalate absorption measured with a standardized [13c2]oxalate absorption test. J Urol 2003; 169:687-690.
36. Zimmermann D, Hesse A, von Unruh G. Influence of a high-oxalate diet on intestinal oxalate absorption. World J Urol 2005; 23:324-329.
37. Marengo SR, Romani AMP. Oxalate in renal stone disease: the terminal metabolite that just won't go away. Nat Clin Pract Nephrol 2008; 4:368-377.
38. Holmes RP, Goodman HO, Assimos DG. Contribution of dietary oxalate to urinary oxalate excretion. Kidney Int 2001; 59:270-276.
39. Singh PP, Kothari LK, Sharma DC, Saxena SN. Nutritional value of foods in relation to their oxalic acid content. Am J Clin Nutr 1972; 25:1147-1152.
40. Chai W, Liebman M. Assessment of oxalate absorption from almonds and black beans and with and without the use of an extrinsic label. J Urol 2004; 172:953-957.
41. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77-84.
42. Liebman M, Costa G. Effects of calcium and magnesium on urinary oxalate excretion after oxalate loads. J Urol 2000; 163:1565-1569.
43. Hess B, Jost C, Zipperle L, et al. High-calcium intake abolishes hyperoxaluria and reduces urinary crystallization during a 20-fold normal oxalate load in humans. Nephrol Dial Transplant 1998; 13:2241-2247.
44. Knauf F, Ko N, Jiang Z, et al. Net intestinal transport of oxalate reflects passive absorption and Slc26a6-mediated secretion. J Am Soc Nephrol 2011; 22:2247-2255.
45. Freel RW, Whittamore JM, Hatch M. Transcellular oxalate and Cl-absorption in mouse intestine is mediated by the DRA anion exchanger Slc26a3, and Dra deletion decreases urinary oxalate. Am J Physiol Gastrointest Liver Physiol 2013; 305:G520-527.
46. Jiang Z, Asplin JR, Evan AP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 2006; 38:474-478.
47. Freel RW, Hatch M, Green M, Soleimani M. Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. Am J Physiol Gastrointest Liver Physiol 2006; 290:G719-G728.
48. Dawson PA, Russell CS, Lee S, et al. Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. J Clin Invest 2010; 120:706-712.
49. Monico CG, Weinstein A, Jiang Z, et al. Phenotypic and functional analysis of human Slc26a6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis 2008; 52:1096-1103.
50. Hautmann R, Osswald H. Pharmacokinetic studies of oxalate in man. Invest Urol 1979; 16:395-398.
51. Weinman EJ, Frankfurt SJ, Ince A, Sansom S. Renal tubular transport of organic acids: studies with oxalate and para-aminohippurate in the rat. J Clin Invest 1978; 61:801-806.
52. Senekjian HO, Weinman EJ. Oxalate transport by proximal tubule of the rabbit kidney. Am J Physiol 1982; 243:F271-F275.
53. Knight TF, Sansom SC, Senekjian HO, Weinman EJ. Oxalate secretion in the rat proximal tubule. Am J Physiol 1981; 240:F295-F298.
54. Sigmon D, Kumar S, Carpenter B, et al. Oxalate transport in renal tubular cells from normal and stone-forming animals. Am J Kidney Dis 1991; 17:376-380.
55. Chandhoke PS, Fan JIE. Transport of oxalate across the rabbit papillary surface epithelium. J Urol 2000; 164:1724-1728.
56. Robijn S, Hoppe B, Vervaet BA, et al. Hyperoxaluria: a gut-kidney axis. Kidney Int 2011; 80:1146-1158.
57. Wilson DM, Liedtke RR. Modified enzyme-based colorimetric assay of urinary and plasma oxalate with improved sensitivity and no ascorbate interference: reference values and sample handling procedures. Clin Chem 1991; 37:1229-1235.
58. Fry ID, Starkey BJ. The determination of oxalate in urine and plasma by high performance liquid chromatography. Ann Clin Biochem 1991; 28:581-587.
59. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013; 369:649-658.
60. Williams EL, Acquaviva C, Amoroso A, et al. Primary hyperoxaluria type 1: update and additional mutation analysis of the Agxt gene. Hum Mutat 2009; 30:910-917.
61. Rumsby G. University College London Hospitals. Primary hyperoxaluria mutation database 2015; https://www. uclh. nhs. uk/OURSERVICES/SERVICEA-Z/PATH/PATHBIOMED/CBIO/Pages/Phmdatabase. aspx [Accessed 1 January 2016]
62. Mandrile G, van Woerden CS, Berchialla P, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the Agxt mutation type. Kidney Int 2014; 86:1197-1204.
63. Allison MJ, Cook HM, Milne DB, et al. Oxalate degradation by gastrointestinal bacteria from humans. J Nutr 1986; 116:455-460.
64. Rankin AC, Walsh SB, Summers SA, et al. Acute oxalate nephropathy causing late renal transplant dysfunction due to enteric hyperoxaluria. Am J Transplant 2008; 8:1755-1758.
65. Whittamore J, Hatch M. Chronic metabolic acidosis reduces urinary oxalate excretion and promotes intestinal oxalate secretion in the rat. Urolithiasis 2015; 43:489-499.
66. Kumar R, Lieske JC, Collazo-Clavell ML, et al. Fat malabsorption and increased intestinal oxalate absorption are common after Roux-En-Y gastric bypass surgery. Surgery 2011; 149:654-661.
67. Stewart CS, Duncan SH, Cave DR. Oxalobacter formigenes and its role in oxalate metabolism in the human gut. FEMS Microbiol Lett 2004; 230:1-7.
68. Gulhan B, Turkmen K, Aydin M, et al. The relationship between serum oxalic acid, central hemodynamic parameters and colonization by Oxalobacter formigenes in hemodialysis patients. Cardiorenal Med 2015; 5:164-174.
69. Hatch M, Freel RW. A human strain of Oxalobacter (Hc-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. Urolithiasis 2013; 41:379-384.
70. Lefaucheur C, Hill GS, Amrein C, et al. Acute oxalate nephropathy: a new etiology for acute renal failure following nonrenal solid organ transplantation. Am J Transplant 2006; 6:2516-2521.
71. Hoppe B, Dittlich K, Fehrenbach H, et al. Reduction of plasma oxalate levels by oral application of Oxalobacter formigenes in 2 patients with infantile oxalosis. Am J Kidney Dis 2011; 58:453-455.
72. Gross O, Thomas CJ, Guarda G, Tschopp J. The inflammasome: an integrated view. Immunol Rev 2011; 243:136-151.
73. LorenzG, Darisipudi MN, Anders H-J. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014; 29:41-48.
74. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1b secretion. J Clin Invest 2013; 123:236-246.
75. Kasimsetty SG, DeWolf SE, Shigeoka AA, McKay DB. Regulation of TLR2 and NLRP3 in primary murine renal tubular epithelial cells. Nephron Clin Pract 2014; 127:119-123.
76. Shigeoka AA, Mueller JL, Kambo A, et al. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol 2010; 185:6277-6285.
77. Zhuang Y, Hu C, Ding G, et al. Albumin impairs renal tubular tight junctions via targeting the NLRP3 inflammasome. Am J Physiol Renal Physiol 2015; 308:F1012-F1019.
78. Gao P, He FF, Tang H, et al. Nadph oxidase-induced Nalp3 inflammasome activation is driven by thioredoxin-interacting protein which contributes to podocyte injury in hyperglycemia. J Diabetes Res 2015; 2015:504761.
79. Haque S, Lan X, Wen H, et al. HIV promotes NLRP3 inflammasome complex activation in murine HIV-associated nephropathy. Am J Pathol 2016; 186:347-358.
80. Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens 2014; 23:204-210.
81. Knauf F, Asplin JR, Granja I, et al. Nalp3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 2013; 84:895-901.
82. Darisipudi M, Knauf F. An update on the role of the inflammasomes in the pathogenesis of kidney diseases. Pediatr Nephrol 2016; 31:535-544.
83. Joshi S, Wang W, Peck AB, Khan SR. Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys. J Urol 2015; 193:1684-1691.
84. Iyer SS, Pulskens WP, Sadler JJ, et al. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. Proc Natl Acad Sci USA 2009; 106:20388-20393.
85. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010; 21:1732-1744.
86. Rusai K, Huang H, Sayed N, et al. Administration of interleukin-1 receptor antagonist ameliorates renal ischemia-reperfusion injury. Transpl Int 2008; 21:572-580.
87. Hung AM, Ellis CD, Shintani A, et al. Il-1b receptor antagonist reduces inflammation in hemodialysis patients. J Am Soc Nephrol 2011; 22:437-442.
88. Coll RC, Robertson AAB, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015; 21:248-255.
89. Scarpioni R, Rigante D, Cantarini L, et al. Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1beta monoclonal antibody canakinumab. Clin Rheumatol 2015; 34:1311-1316.
90. Kuemmerle-Deschner JB, Haug I. Canakinumab in patients with cryopyrinassociated periodic syndrome: an update for clinicians. Ther Adv Musculoskelet Dis 2013; 5:315-329.
91. Dubois EA, Rissmann R, Cohen AF. Rilonacept and canakinumab. Br J Clin Pharmacol 2011; 71:639-641.
92. Jesus AA, Goldbach-Mansky R. Il-1 blockade in autoinflammatory syndromes. Annu Rev Med 2014; 65:223-244.
93. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: rationale and design of the canakinumab anti-inflammatory thrombosis outcomes study (cantos). Am Heart J 2011; 162:597-605.
94. Thompson S, James M, Wiebe N, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015; 26:2504-2511.
95. Navaneethan SD, Schold JD, Arrigain S, et al. Cause-specific deaths in nondialysis-dependent CKD. J Am Soc Nephrol 2015; 26:2512-2520.
96. Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase Iib randomized, placebo-controlled trial. Circulation 2012; 126:2739-2748.
97. Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1b monoclonal antibody. Clin Pharmacokinet 2012; 51:e1-e18.
98. Radin A, Marbury T, Osgood G, Belomestnov P. Safety and pharmacokinetics of subcutaneously administered rilonacept in patients with well controlled end-stage renal disease (Esrd). J Clin Pharmacol 2010; 50:835-841.
99. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009; 187:61-70.
100. Juliana C, Fernandes-Alnemri T, Wu J, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem 2010; 285:9792-9802.
101. Ahn H, Kim J, Jeung E-B, Lee G-S. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology 2014; 219:315-322.
102. Ahn H, Kim J, Lee M-J, et al. Methylsulfonylmethane inhibits NLRP3 inflammasome activation. Cytokine 2015; 71:223-231.
103. He Y, Varadarajan S, Muñ oz-Planillo R, et al. 3, 4-methylenedioxy-B-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem 2014; 289:1142-1150.
104. Coll RC, Robertson AAB, Butler MS, et al. The cytokine release inhibitory drug CRID3 targets ASC oligomerisation in the NLRP3 and AIM2 inflammasomes. PLoS One 2011; 6:e29539.
105. Perregaux DG, McNiff P, Laliberte R, et al. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther 2001; 299:187-197.
106. Laliberte RE, Perregaux DG, Hoth LR, et al. Glutathione S-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1b posttranslational processing. J Biol Chem 2003; 278:16567-16578.
107. Youm Y-H, Nguyen KY, Grant RW, et al. The ketone metabolite [Beta]-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015; 21:263-269.
108. Mulay SR, Eberhard JN, Pfann V, et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57bl/6 mice. Am J Physiol Renal Physiol 2016; 123:236-246.
109. Elgstoen KBP, Johnsen LF, Woldseth B, et al. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria. Nephrol Dial Transplant 2010; 25:2341-2345.
110. Hoppe B, Kemper MJ, Bokenkamp A, et al. Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 1999; 56:268-274.
111. Ogawa Y, Machida N, Ogawa T, et al. Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria. Urol Res 2006; 34:12-16.
112. Hopp K, Cogal AG, Bergstralh EJ, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 2015; 26:2559-2570.
113. Porowski T, Zoch-Zwierz W, Konstantynowicz J, et al. Reference values of plasma oxalate in children and adolescents. Pediatr Nephrol 2008; 23:1787-1794.
114. Harris AH, Freel RW, Hatch M. Serum oxalate in human beings and rats as determined with the use of ion chromatography. J Lab Clin Med 2004; 144:45-52.
115. Ogura H. Determinations of oxalate in urine and plasma by capillary electrophoresis. Jap J Urol 2000; 91:547-555.
116. Manoharan M, Schwille PO. Measurement of oxalate in human plasma ultrafiltrate by ion chromatography. J Chromatogr B Biomed Sci Appl 1997; 700:261-268.
117. Elgstoen KBP. Liquid chromatography-tandem mass spectrometry method for routine measurement of oxalic acid in human plasma. J Chromatogr B 2008; 873:31-36.
118. Hoppe B, Kemper MJ, Hvizd MG, et al. Simultaneous determination of oxalate, citrate and sulfate in children's plasma with ion chromatography. Kidney Int 1998; 53:1348-1352.
119. Ogi M, Abe R, Nishitani T, et al. The oxalate level in ultrafiltrate fluid collected from a dialyzer is useful for estimating the plasma oxalate level in hemodialysis patients. Clin Exp Nephrol 2006; 10:118-123.
120. Mori S, Beppu T. Secondary renal oxalosis. a statistical analysis of its possible causes. Acta Pathol Jpn 1983; 33:661-669.
121. Chen SM, Chen TW, Lee YH, et al. Renal excretion of oxalate in patients with chronic renal failure or nephrolithiasis. J Formos Med Assoc 1990; 89:651-656.
122. Tomson CR, Channon SM, Ward MK, Laker MF. Oxalate retention in chronic renal failure: tubular vs glomerular diseases. Clin Nephrol 1989; 32:87-95.
123. Hoppe B, Kemper MJ, Bokenkamp A, Langman CB. Plasma calcium-oxalate saturation in children with renal insufficiency and in children with primary hyperoxaluria. Kidney Int 1998; 54:921-925.
124. Prenen JAC, Mees EJD, Boer P. Plasma oxalate concentration and oxalate distribution volume in patients with normal and decreased renal function. Eur J Clin Invest 1985; 15:45-49.
125. Gershman B, Sheth S, Dretler SP, et al. Relationship between glomerular filtration rate and 24-hour urine composition in patients with nephrolithiasis. Urology 2012; 80:38-42.
126. Marangella M, Cosseddu D, Petrarulo M, et al. Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol Dial Transplant 1993; 8:1333-1337.
127. Watts RWE, Veall N, Purkiss P. Oxalate dynamics and removal rates during haemodialysis and peritoneal dialysis in patients with primary hyperoxaluria and severe renal failure. Clin Sci 1984; 66:591-597.
128. Tomson CRV, Channon SM, Ward MK, Laker MF. Plasma oxalate concentration, oxalate clearance and cardiac function in patients receiving haemodialysis. Nephrol Dial Transplant 1989; 4:792-799.